Dr.Mazzola’s main research focuses on different aspects of cancer biostatistics: within the general framework of risk prediction of invasive breast cancer following diagnoses of precancerous events, he has been mainly dealing with building expansions of the BRCAPRO model to account for diagnoses of: DCIS (Ductal Carcinoma in Situ) and Contralateral breast cancer.
Also, he is the PI of the recently awarded R03 grant “Risk assessment in atypical breast hyperplasia” aiming at the construction and validation of a new and comprehensive approach for risk assessment in women diagnosed with atypical hyperplasia of the breast (with G.Parmigiani, Ph.D, Su-Chun Cheng, Sc.D, Kevin Hughes, MD Ph.D).
On a more theoretical end, he is focusing on Monte Carlo techniques for calibration of general microsimulation models
(with G.Parmigiani, Ph.D).
As a collaborative biostatistician, his other areas of interest are: Hematology (with D.Neuberg, Sc.D), Brain Cancer (with R.Segal, MD Ph.D), HIV (with R.Gelman, Ph.D).
He is also responsible of the preparation of educational material on clinical trials and reproducible research for in-person and online sessions to be conducted in conjunction with the Dana-Farber Cancer Institute’s Clinical Trials Education Office (with P.Catalano, Sc.D).
Dr.Mazzola received his M.S. in Mathematics from the Università degli Studi di Milano, Italy in 2002 with a thesis on spatial statistics.
He then received a M.S. in Biostatistics from the Università degli Studi di Milano-Bicocca in 2005 with a thesis on Generalized linear models in ecotoxicology.
In 2010 he received his Ph.D. in Statistics from the Università Commerciale L.Bocconi, Milano, Italy with a thesis on Lèvy processes.
He has been a postdoctoral fellow under the mentorship of Prof. Giovanni Parmigiani from November 2010 at the Department of Biostatistics and Computational Biology at Dana-Farber Cancer Institute.
He became a Research Associate in the same department in November 2012.
Stone R., Mazzola E., Neuberg D. et al. A phase III open label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia (sAML). Accepted for publication on J Clin Oncol, 2014.
Mazzola, E., Chipman J., Cheng S.-C. and Parmigiani G. Recent BRCAPRO updates significantly improve calibration. Cancer Epidemiology Biomarkers & Prevention, 23, 1689-1695, 2014.
Mazzola, E., Cheng, S.-C. and Parmigiani, G. The Penetrance of Ductal Carcinoma in Situ Among BRCA1 and BRCA2 Mutation Carriers.
Breast Cancer Res Treat, November 2012; DOI: 10.1007/s10549 -012-2345-5.
Coopey, S.B., Mazzola, E., Buckley, J.M., Sharko, J., Belli, A.K., Kim, E., Polufriaginof, F., Parmigiani, G., Garber, J.E., Smith, B.L., Gadd, M.A., Specht M.C., Guidi A.J., Roche, C.A. and Hughes, K.S. Clarifying the Risk of Breast Cancer in Women with Atypical Breast Lesions.
Breast Cancer Res Treat, November 2012; DOI: 10.1007/s10549-012-2318-8.
Mazzola, E., and Muliere, P., Reviewing alternative characterizations of Meixner process. Probability Surveys 8: 127-154, 2011. DOI: 10.1214/11-PS177.